Vienna, Austria - Hookipa Biotech AG (“Hookipa”), a company pioneering an innovative class of immunotherapies for oncology and infectious diseases, today announced the appointment of Dr. Jan van de Winkel as Chairman of its Board of Directors.
Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces that it has been awarded UK Best Start-up Biotech at the OBN Awards, which took place at Oxford Town Hall.
Copenhagen, Denmark - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has held an official ground breaking ceremony for a new US$25 million expansion at its Copenhagen site. This site houses Xellia’s headquarters and is the Company’s largest product manufacturing plant.
San Mateo, CA - Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, has won ‘Best Implementation of Digital Healthcare’ at the prestigious OBN Awards 2017. The awards celebrate innovation and achievement across the UK life sciences industry and the winners were selected by an esteemed panel of judges.
Sydney, Australia - Atomo Diagnostics, a world leader in innovative point-of-care, rapid diagnostic devices, announced today that its Atomo HIV Self Test has been granted CE Marking by a European Union Notified Body.
IRVINE, CA and AMSTERDAM – Breast cancer is the most feared type of cancer among women in Germany, according to a recent representative survey commissioned by Agendia, a world leader in personalized medicine and molecular cancer diagnostics. 21% of the over 1,000 women questioned in a telephone survey carried out by KANTAR Emnid said that of all cancers, they most feared breast cancer, slightly ahead of colon and lung cancer (both at 20%). Over half (57%) of respondents said that they, or a relative or friend, have already been affected by breast cancer.
London: Instinctif Partners, the business communications consultancy, congratulates all of the winners of the OBN Awards 2017, in particular its clients Microbiotica for being awarded the ‘Best Start-up Biotech Company, and Adherium for winning the ‘Best Implementation of Digital Healthcare’.
Nijmegen, the Netherlands - Synthon today announced that it has successfully concluded the decentralized procedures for glatiramer acetate 40 mg/ml pre-filled syringe for the treatment of relapsing forms of multiple sclerosis and received regulatory approval in Europe. Synthon’s three-times-a-week glatiramer acetate is a therapeutically equivalent version of the originator medicine Copaxone®* 40mg.
Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX, the “Company”), a life science company focused on skin health, has passed third party cellular toxicity tests for its SkinBiotix® technology, confirming previous in-house observations on its safety and applicability.
The Company has also been progressing its three programmes and is on track to hit its key milestone of first studies in man in 2018.
Kingston, Canada – PnuVax Incorporated, an organization dedicated to the production of high quality vaccines and biopharmaceuticals for the promotion of public health worldwide, today announced that it is the recipient of a $29.4 million USD ($36 million CDN) grant. The grant will be used to further develop and clinically evaluate PnuVax’s innovative pneumococcal conjugate vaccine. Milestone payments will be received over the next three years as the vaccine progresses from process development through to biomanufacturing scale-up and proof-of-concept clinical trials.
Bordeaux, France – LNC Therapeutics, a company specialized in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, today announced that it has raised a €6.5 million Series C funding round.
Houston, Texas and Tuebingen, Germany – Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA201, its first T-cell Receptor (TCR)-transduced adoptive cell therapy program. IMA201 is an investigational immunotherapy which uses Immatics’ proprietary ACTengine® approach, and is based on genetically engineering a patient’s own T-cells to express an exogenous TCR. The goal is to redirect and activate the cells to treat solid tumors. The single-center clinical study is now open for enrollment at The University of Texas MD Anderson Cancer Center in Houston, Texas.
IRVINE, CA and AMSTERDAM – Agendia, a world leader in personalized medicine and molecular cancer diagnostics, is supporting Breast Cancer Awareness Month with activities throughout late September and October across the United States and Europe around the theme of ‘Breast Cancer – Let’s Make It Personal’.
London, UK and Carlsbad, CA, USA – DNAe, the inventor of semiconductor based genomic analysis technologies, and the developer of a new, game-changing test for diagnosis of bloodstream infections that can lead to sepsis, previews its LiDia™ bloodstream infection (BSI) test today at the ‘Technology vs Infectious Diseases’ Summit held at the Royal Institution in London.
Oxford, UK: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces its half year results for the six months ended 31 July 2017 (H1 17).
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the ‘Group’), the global pharmaceutical and services company and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX, ‘Cumberland’), a U.S. specialty pharmaceutical company, announced today the promotional launch of Totect® (dexrazoxane hydrochloride), in the U.S.
LONDON, BOSTON, TOKYO, SAN FRANCISCO — The “EvaluateMedTech World Preview 2017, Outlook to 2022” report from life science commercial intelligence firm Evaluate Ltd, reveals Medtronic was the leading medtech company in 2016 with sales of almost $30bn and will retain the crown in 2022 with sales forecast to reach $37.7bn; Abbott to jump to 3rd place as its acquisition of St. Jude creates the world’s second largest cardiology company.
Cambridge, UK – Investing in the UK’s innovative life sciences and biotech sector just became more accessible to a wide spectrum of investors, with Capital Cell, Europe’s first dedicated Life Sciences crowdfunding platform. Today Capital Cell has formally ‘opened to investors’ with the first four investment opportunities now live on the platform. These opportunities include a company developing alternatives to antibiotics and an equine health company.
San Mateo, CA - Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today announced the appointment of Timothy A. Marcotte as its new Chief Financial Officer. Mr. Marcotte will join the Company’s leadership team and be based out of the Company’s U.S. headquarters in San Mateo, California.
Cambridge, UK – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announces that Lotta Ljungqvist has today been appointed as a Non-Executive Director of the Company.